Wall Street analysts expect Global Blood Therapeutics Inc (NASDAQ:GBT) to post earnings of ($0.88) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Global Blood Therapeutics’ earnings. The lowest EPS estimate is ($1.02) and the highest is ($0.72). Global Blood Therapeutics posted earnings of ($0.94) per share during the same quarter last year, which suggests a positive year over year growth rate of 6.4%. The firm is scheduled to announce its next earnings results on Tuesday, February 26th.
According to Zacks, analysts expect that Global Blood Therapeutics will report full-year earnings of ($3.39) per share for the current fiscal year, with EPS estimates ranging from ($3.54) to ($3.20). For the next fiscal year, analysts expect that the company will post earnings of ($3.74) per share, with EPS estimates ranging from ($4.24) to ($3.03). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Global Blood Therapeutics.
Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings data on Tuesday, November 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.02. During the same period last year, the company earned ($0.66) earnings per share.
A number of research analysts have recently issued reports on GBT shares. Cantor Fitzgerald reissued a “buy” rating and issued a $96.00 price objective on shares of Global Blood Therapeutics in a research note on Wednesday, October 17th. HC Wainwright set a $125.00 price target on Global Blood Therapeutics and gave the stock a “buy” rating in a research note on Thursday, September 13th. Cowen reaffirmed a “buy” rating and set a $83.00 price target on shares of Global Blood Therapeutics in a research note on Monday, August 13th. BidaskClub downgraded Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, September 19th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating and set a $75.00 price target on shares of Global Blood Therapeutics in a research note on Sunday, August 5th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. Global Blood Therapeutics has a consensus rating of “Buy” and a consensus price target of $80.20.
Shares of NASDAQ:GBT opened at $39.89 on Friday. The stock has a market capitalization of $2.18 billion, a PE ratio of -14.45 and a beta of 3.70. Global Blood Therapeutics has a 1 year low of $31.50 and a 1 year high of $68.05.
In related news, insider Lesley Ann Calhoun sold 2,004 shares of the company’s stock in a transaction that occurred on Friday, August 17th. The stock was sold at an average price of $49.89, for a total transaction of $99,979.56. Following the transaction, the insider now directly owns 1,342 shares of the company’s stock, valued at approximately $66,952.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 4.40% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. PNC Financial Services Group Inc. increased its holdings in Global Blood Therapeutics by 740.3% during the 3rd quarter. PNC Financial Services Group Inc. now owns 4,353 shares of the company’s stock worth $165,000 after purchasing an additional 3,835 shares in the last quarter. Tiverton Asset Management LLC bought a new position in shares of Global Blood Therapeutics in the second quarter valued at approximately $166,000. Quantitative Systematic Strategies LLC bought a new position in shares of Global Blood Therapeutics in the second quarter valued at approximately $203,000. Public Employees Retirement Association of Colorado grew its holdings in shares of Global Blood Therapeutics by 148.3% in the third quarter. Public Employees Retirement Association of Colorado now owns 5,512 shares of the company’s stock valued at $209,000 after acquiring an additional 3,292 shares in the last quarter. Finally, Great West Life Assurance Co. Can grew its holdings in shares of Global Blood Therapeutics by 42.0% in the second quarter. Great West Life Assurance Co. Can now owns 4,969 shares of the company’s stock valued at $224,000 after acquiring an additional 1,469 shares in the last quarter. 99.01% of the stock is owned by hedge funds and other institutional investors.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
Further Reading: What does cost of debt say about a company’s financial health?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.